Log in

ASO Author Reflections: Neoadjuvant Chemotherapy versus Definitive Chemoradiation Therapy for Locally Advanced Cervical Esophageal Cancer: A Retrospective Study

  • ASO Author Reflections
  • Published:
Annals of Surgical Oncology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Germany)

Instant access to the full article PDF.

References

  1. Nakajima Y, Tachimori H, Miyawaki Y, et al. A survey of the clinical outcomes of cervical esophageal carcinoma surgery focusing on the presence or absence of laryngectomy using the National Clinical Database in Japan. Esophagus. 2022;19:569–75.

    Article  PubMed  Google Scholar 

  2. Shah MA, Kennedy EB, Catenacci DV, et al. Treatment of locally advanced esophageal carcinoma: ASCO guideline. J Clin Oncol. 2020;38:2677–94.

    Article  PubMed  Google Scholar 

  3. Kato K, Ito Y, Daiko H, et al. A randomized controlled Phase III trial comparing doublet chemotherapy, triplet chemotherapy, and doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced esophageal cancer: the JCOG1109 NExT study. Lancet. (in press).

  4. Kubo Y, Makino T, Yamasaki M, et al. Three-course neoadjuvant chemotherapy associated with unfavorable survival of non-responders to the first two courses for locally advanced esophageal cancer. Ann Surg Oncol. 2023;30:5899–907.

    Article  PubMed  Google Scholar 

  5. Kubo Y, Nozaki R, Igaue S, et al. Neoadjuvant chemotherapy improves feasibility of larynx preservation and prognosis for resectable locally advanced cervical esophageal cancer. Ann Surg Oncol. 2024. https://doi.org/10.1245/s10434-024-15432-4.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Hiroyuki Daiko MD, PhD, FACS.

Ethics declarations

Disclosures

Ken Kato reports funding from Merck Sharp & Dohme Corp. (MSD), Ono Pharmaceuticals, Bristol Myers Squibb (BMS), Beigene, Shionogi, Merck Biopharma, Oncolys BioPharma, Daiichi Sankyo, Novartis, Taiho Pharmaceutical, Janssen, AstraZeneca, and Chugai, paid to his institution. Yuto Kubo and Hiroyuki Daiko have no disclosures to declare in relation to this work.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article refers to: Kubo Y, Nozaki R, Igaue S, et al. Neoadjuvant chemotherapy improves feasibility of larynx preservation and prognosis for resectable locally advanced cervical esophageal cancer. Ann Surg Oncol. 2024. https://doi.org/10.1245/s10434-024-15432-4.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kubo, Y., Kato, K. & Daiko, H. ASO Author Reflections: Neoadjuvant Chemotherapy versus Definitive Chemoradiation Therapy for Locally Advanced Cervical Esophageal Cancer: A Retrospective Study. Ann Surg Oncol (2024). https://doi.org/10.1245/s10434-024-15520-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1245/s10434-024-15520-5

Navigation